Last reviewed · How we verify
Prasugrel monotherapy
At a glance
| Generic name | Prasugrel monotherapy |
|---|---|
| Also known as | PCI with the SYNERGY® stent |
| Sponsor | Pedro A. Lemos |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Minor bleeding
- Skin Rashes and Itching
- BARC 3 bleeding event
Key clinical trials
- Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI (PHASE4)
- Prasugrel Monotherapy Reduced Dose in Acute and Chronic Coronary Syndrome Patients After Percutaneous Coronary Intervention (PROMOTE) (PHASE4)
- Multivessel TALENT (NA)
- The Switching Antiplatelet-9 (SWAP-9) Study (PHASE4)
- Switching From Dual Antiplatelet Therapy to Monotherapy With Potent P2Y12 Inhibitors (PHASE4)
- Safety and Efficacy of Very Short DAPT in Older Patients Undergoing PCI (PHASE3)
- The Study of CYP2C19 Genotype-Guided Clopidogrel Treatment Models (NA)
- Comparison Of Reduced DAPT Followed by P2Y12 Inhibitor Monotherapy With Prasugrel vs stAndard Regimen in STEMI Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |